Glucose‐6‐phosphate dehydrogenase: A possible clinical indicator for prostatic carcinoma

53Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Any system of biochemical analysis that can be used to detect chemical differences between normal and malignant cells may add potentially valuable information to complement the histologic data which provide the practical definition of human prostatic carcinoma. A difference (P < 0.0001) was observed in the levels of glucose‐6‐phosphate dehydrogenase (G‐6‐PD) activity in prostatic tissue with benign hyperplasia and prostatic carcinoma. Measured as a function of the amount of protein extracted from whole‐tissue homogenates, the values for G‐6‐PD activity in prostatic carcinoma are almost four times those measured for benign prostatic hyperplasia. The degree of elevation of the activity of this enzyme suggests a correlation between enzymatic activity and clinical prognosticators, ie., histotogic differentiation and clinical stage. Copyright © 1982 American Cancer Society

Cite

CITATION STYLE

APA

Zampella, E. J., Bradley, E. L., & Pretlow, T. G. (1982). Glucose‐6‐phosphate dehydrogenase: A possible clinical indicator for prostatic carcinoma. Cancer, 49(2), 384–387. https://doi.org/10.1002/1097-0142(19820115)49:2<384::AID-CNCR2820490229>3.0.CO;2-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free